INSP
resolvedInspire Medical Systems, Inc.
Price Chart
Gap Information
Score Analysis
Model 1: Rerate Score
Model 2: Trade Probability
AI Thesis
Inspire Medical Systems' massive 22.9% gap up reflects Wall Street's potential repricing of the Obstructive Sleep Apnea (OSA) growth narrative. Inspire has been a high-beta med-tech story that sold off sharply over the past 18 months as investors worried about slowing growth trajectory, procedure volume softness, and the path to sustainable profitability. A gap of this magnitude strongly suggests that quarterly results decisively refuted the bear case — likely showing reaccelerating revenue growth, expanding gross margins, and/or upward guidance revisions that signal the company's implantable hypoglossal nerve stimulation therapy is gaining adoption faster than the skeptical consensus assumed. The rerating probability is meaningful because INSP operates in a large, underpenetrated market (millions of OSA patients who fail or refuse CPAP therapy), and the stock had been de-rated to a level that priced in significant disappointment. If this print demonstrates operating leverage — revenue outpacing opex growth, narrowing losses, or a credible timeline to breakeven — investors will need to model higher long-term revenue and earlier profitability. The 2.24x volume signal confirms institutional participation, not just a short squeeze, suggesting fundamental repositioning rather than transient momentum. The key question for sustainability is whether the new price level holds above the 10-EMA ($53.31) and whether management's forward commentary supports the revised growth trajectory.
Analyzed by rerate-v2+glm-5.2 · Aug 6, 2026
Catalysts
- Revenue reacceleration or upside surprise demonstrating sustained demand for Inspire therapy
- Raised full-year guidance signaling management confidence in procedure volume growth
- Improving gross margins from manufacturing scale and operational efficiency
- Expansion of trained implanting physician centers accelerating market penetration
- Path to profitability becoming clearer with narrowing quarterly losses or operating leverage
- FDA label expansion or new clinical data supporting broader OSA indications
- Possible positive coverage decisions from additional payors expanding reimbursement
Risks
- CPAP competitive dynamics — ResMed and Philips dominate sleep apnea with cheaper alternatives
- High valuation multiple even after selloff leaves limited room for execution missteps
- Slowing procedure volume growth in subsequent quarters could reverse the rerating
- Reimbursement risk if payors tighten coverage criteria for hypoglossal nerve stimulation
- Limited operating history and unproven long-term durability of implants
- Single-product company with concentrated risk — no diversification if Inspire adoption stalls
- Stock had been in sustained downtrend — this gap may face overhead supply and profit-taking pressure
Technical Setup
Forward Returns
Outcomes calculated Aug 11, 2026
Post-Gap Validation — 5-Day Follow-Through
Day-by-Day Price Action
| Day | Close | High | Low | Volume |
|---|---|---|---|---|
| Day 1 | $60.09 | $63.34 | $59.76 | 1.45M |
| Day 2 | $58.89 | $60.44 | $58.68 | 681.9K |
| 📍 Day 3 | $60.16 | $60.51 | $58.28 | 538.9K |
| Day 4 | $59.72 | $61.31 | $59.35 | 585.4K |
| Day 5 | Pending | |||
Signal Breakdown
Gap partially filled (44%) — ambiguous
Moderate volume decline (60%)
Lower highs with peak close on day 1 — price action suggests distribution, not accumulation
Drew down 9.1% from gap close — significant give-back
No fundamental data to evaluate beat quality
Analysis updated Aug 11, 2026